SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
Clinical trials for SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE trials appear
Sign up with your email to follow new studies for SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to slow lung damage in scleroderma patients
Disease control Recruiting nowThis study looks at whether adding an anti-fibrotic medication to a two-drug immune suppression regimen helps people with scleroderma-related lung disease. About 35 adults will take part, and their lung function will be checked over a year. The goal is to see if the extra drug ca…
Matched conditions: SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
Sponsor: University of Patras • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
New hope for scleroderma lung disease: belimumab trial targets breathing and skin
Disease control Recruiting nowThis study tests whether the drug belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis (scleroderma) that has caused lung scarring. About 300 participants will receive either belimumab or a placebo, added to their usual care, for 52 wee…
Matched conditions: SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE
Phase: PHASE2, PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC